相关实验视频

Updated: Jun 16, 2025

Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres

Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres

Published on: February 2, 2015

在初级开放角眼中,对三项微快速研究进行了聚合分析,评估了不同度的应用性线粒素C

Julián Garcia-Feijoo¹, Juan F Batlle², Florent Aptel³

¹Departamento de Oftalmologia, Universidad Complutense, Hospital Clínico San Carlos, OFTARED, IdISSC, Planta 3, Madrid, Spain. jgarciafeijoo@hotmail.com.

Ophthalmology and therapy

|May 23, 2025

概括

在PRESERFLO MicroShunt手术期间,米托米辛C (MMC) 的较高度导致了青光眼患者的更好的结果. 与0.2mg/ml组相比,0.4mg/mlMMC组显示出更大的眼内压力降低和更高的成功率.

科学领域:

眼科医生眼科眼科
玻璃眼的手术玻璃眼的手术
手术设备手术设备

背景情况:

PRESERFLO MicroShunt是一种用于外部过手术的聚[烯-块-异布烯-块-烯] (SIBS) 装置.
之前的试验评估了用Mitomycin C (MMC) 植入MicroShunt的2年有效性和安全性.
本综合分析使用两种不同的MMC度 (0.2 mg/ml与0.4 mg/ml) 进行对比结果.

研究的目的:

为了比较PRESERFLO MicroShunt植入剂的2年有效性和安全性,使用0.2 mg/ml与0.4 mg/ml米托米辛C (MMC) 相比.
评估不同MMC度对眼内压力 (IOP) 和绿眼病药物使用的影响.
评估与不同的MMC度相关的完全成功率和不良事件.

主要方法:

对三项前性,开放性临床试验 (NCT00772330,NCT01563237,NCT02177123) 的综合分析.
包括125名年龄在18-85岁之间的患者,主要的开角玻璃眼,在最大限度的医疗治疗中不受控制.
患者接受了0.2 mg/ml (n=58) 或0.4 mg/ml (n=67) MMC的MicroShunt植入,并进行了2年后的结果评估.

主要成果:

与0.4 mg/ml MMC (-40.9%) 相比,与0.2 mg/ml MMC (-34.5%) (P<0.05) 相比,观察到更大的IOP平均减少.
在0.4毫克/毫升组中,两年后无药患者 (85.2%与58.0%,P<0.01) 和完全成功率 (71.6%与48.3%,P<0.01) 显著更高.
在两个MMC度组之间,与程序/设备相关的不良事件或严重不良事件没有显著差异.

结论:

与0.2 mg/ml相比,更高的米托米辛C度 (0.4 mg/ml) 导致较低的2年IOP和绿眼的药物使用.
0.4 mg/ml MMC 组在 MicroShunt 植入后 2 年表现出显著更高的完全成功率.
结果表明,0.4 mg/ml的MMC可能更有效,指导外科选择,等待进一步的受控试验数据.

关键词:

抗纤维素剂是一种抗纤维素剂.眼镜的过手术是眼镜镜的过手术.货币市场中心MMC 在MicroShunt中,我们可以使用MicroShunt.主要的开放角光眼.这就是SIBSS.

更多相关视频

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...